A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis

Summary

This is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of CM310 in subjects with moderate-to-severe atopic dermatitis.

Timeline

Start

2024-03-30

Primary completion

2026-03-30

Completion

2026-03-30

Drugs

Indications